

## Sunesis Pharmaceuticals to Report Second Quarter 2007 Financial Results

July 26, 2007 1:26 PM ET

SOUTH SAN FRANCISCO, Calif., July 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ --

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that management will hold an investor conference call on Thursday, August 2, 2007 at 10:30 a.m. ET/7:30 a.m. PT to discuss financial results for the second quarter 2007.

Individual and institutional investors can access the call via (800) 479-9001 (U.S. and Canada) or (719) 457-2618 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at <http://www.sunesis.com>. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

### About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit <http://www.sunesis.com>.

### Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.

### SOURCE Sunesis Pharmaceuticals, Inc.

investors, Eric Bjerkholt, SVP, Corp. Development & Finance of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals, Inc.

<http://www.sunesis.com>

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX